NO146200C - Analogifremgangsmaate til fremstilling av terapeutisk virksomme 16-oksygenerte prostansyrederivater - Google Patents

Analogifremgangsmaate til fremstilling av terapeutisk virksomme 16-oksygenerte prostansyrederivater

Info

Publication number
NO146200C
NO146200C NO751039A NO751039A NO146200C NO 146200 C NO146200 C NO 146200C NO 751039 A NO751039 A NO 751039A NO 751039 A NO751039 A NO 751039A NO 146200 C NO146200 C NO 146200C
Authority
NO
Norway
Prior art keywords
oxygen
preparation
therapeutically effective
acid derivatives
analogy procedure
Prior art date
Application number
NO751039A
Other languages
English (en)
Other versions
NO146200B (no
NO751039L (no
Inventor
Paul Wadell Collins
Raphael Pappo
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO751039L publication Critical patent/NO751039L/no
Publication of NO146200B publication Critical patent/NO146200B/no
Publication of NO146200C publication Critical patent/NO146200C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
NO751039A 1974-03-26 1975-03-25 Analogifremgangsmaate til fremstilling av terapeutisk virksomme 16-oksygenerte prostansyrederivater NO146200C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/454,913 US3965143A (en) 1974-03-26 1974-03-26 16-Oxygenated prostanoic acid derivatives

Publications (3)

Publication Number Publication Date
NO751039L NO751039L (no) 1975-09-29
NO146200B NO146200B (no) 1982-05-10
NO146200C true NO146200C (no) 1982-08-18

Family

ID=23806587

Family Applications (1)

Application Number Title Priority Date Filing Date
NO751039A NO146200C (no) 1974-03-26 1975-03-25 Analogifremgangsmaate til fremstilling av terapeutisk virksomme 16-oksygenerte prostansyrederivater

Country Status (25)

Country Link
US (1) US3965143A (no)
JP (1) JPS5855142B2 (no)
AR (1) AR207355A1 (no)
AT (1) AT351684B (no)
BE (1) BE827127A (no)
CA (1) CA1040197A (no)
CH (1) CH613443A5 (no)
DE (1) DE2513212C2 (no)
DK (1) DK128075A (no)
EG (1) EG12063A (no)
ES (1) ES436043A1 (no)
FI (1) FI63747C (no)
FR (1) FR2274289A1 (no)
GB (1) GB1492426A (no)
HU (1) HU174973B (no)
IE (1) IE41328B1 (no)
IL (1) IL46919A (no)
NL (2) NL183294B (no)
NO (1) NO146200C (no)
OA (1) OA04910A (no)
PH (1) PH16276A (no)
PL (1) PL100838B1 (no)
SE (1) SE420199B (no)
YU (1) YU39735B (no)
ZA (1) ZA751391B (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113723A (en) * 1972-07-13 1978-09-12 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
US4293704A (en) * 1975-09-25 1981-10-06 American Cyanamid Company Novel 2-substituted-3,4-epoxycyclopentan-1-ones, 2-substituted-3,4-epoxycyclopentan-1-ols, and various 2-substituted-cyclopentenones
US4107441A (en) * 1973-06-15 1978-08-15 American Cyanamid Company Novel 16 hydroxy 15-deoxy-5-cis-prostenoic acids and esters
US4060691A (en) * 1974-03-26 1977-11-29 G. D. Searle & Co. 7-{3-Hydroxy-2-[4-hydroxy-4-(lower alkyl)-trans-1-octen-1-yl]-5-oxocyclopent-1-yl}heptanoic acids and esters
US4192950A (en) * 1976-07-19 1980-03-11 American Cyanamid Company 15-Deoxy-16-hydroxy-16-substituted prostanoic acids and congeners
US4191699A (en) * 1976-07-19 1980-03-04 American Cyanamid Company Various- 15-deoxy-16-hydroxy-16-ethynyl and 16-ethynylsubstituted prostaglandins
US4730065A (en) * 1976-07-19 1988-03-08 American Cyanamid Company 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners
US4061670A (en) * 1976-07-19 1977-12-06 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl and cyclopropyl substituted prostanoic acids and congeners
US4190596A (en) * 1976-07-19 1980-02-26 American Cyanamid Company Various 15-deoxy-16-hydroxy-16-ethynyl and 16-ethynylsubstituted prostaglandins
US4429148A (en) 1976-07-19 1984-01-31 American Cyanamid Company 15-Deoxy-16-hydroxy-16-substituted prostanoic acids and congeners
US4328358A (en) * 1976-07-19 1982-05-04 American Cyanamid Company 15-Deoxy-16-hydroxy-16-substituted prostanoic acids and congeners
AU3437478A (en) * 1977-03-30 1979-09-27 American Cyanamid Co Prostanoic acids and congeners
US4281153A (en) * 1977-08-01 1981-07-28 American Cyanamid 15-Deoxy-16-hydroxy-16-substituted prostanoic acids and congeners
GB2006186A (en) * 1977-08-29 1979-05-02 American Cyanamid Co 15-Deoxy-16-substituted prostanoic acids
GB2009162A (en) * 1977-12-05 1979-06-13 American Cyanamid Co Prostanoic acids and congeners
AU529836B2 (en) * 1977-12-05 1983-06-23 American Cyanamid Company Prostaglandin analog
US4742080A (en) * 1978-02-23 1988-05-03 Miles Laboratories, Inc. Therapeutic method for producing bronchodilation by administration of 15-deoxy-16-hydroxy prostaglandin esters
US4833157A (en) * 1978-02-23 1989-05-23 Miles Inc. Methods of inhibitng gastric secretion with prostaglandin derivatives
US4132738A (en) * 1978-02-23 1979-01-02 Miles Laboratories, Inc. Preparation of 15-deoxy-16-hydroxyprostaglandins
US4239899A (en) * 1979-09-13 1980-12-16 American Cyanamid Company Various 15-deoxy-16-hydroxy-16-ethynyl and 16-ethynylsubstituted prostaglandins
US4322543A (en) * 1979-11-28 1982-03-30 G. D. Searle & Co. 4,5-Unsaturated prostanoic acid derivatives
US4271314A (en) * 1979-11-28 1981-06-02 G. D. Searle & Co. 4,5-Unsaturated prostanoic acid derivatives
US4288629A (en) * 1980-04-03 1981-09-08 American Cyanamid Company 1-Hydroxymethyl-11-deoxy-15-hydroxy-prosten-1-ol-derivatives
US4288632A (en) * 1980-04-03 1981-09-08 American Cyanamid Company 1-Hydroxymethyl-11,16-dihydroxy-prosten-1-ol derivatives
US4310700A (en) * 1980-04-03 1982-01-12 American Cyanamid Company 1-Hydroxylmethyl-11-deoxy-16-hydroxy-prosten-1-ol-derivatives
US4291174A (en) * 1980-04-03 1981-09-22 American Cyanamid Company 1-Hydroxymethyl-15-hydroxy-prosten-1-ol derivatives
US4288630A (en) * 1980-04-03 1981-09-08 American Cyanamid Company 1-Hydroxymethyl-11,15-dihydroxy-prosten-1-ol-derivatives
US4288633A (en) * 1980-04-03 1981-09-08 American Cyanamid Company 1-Hydroxymethyl-11-deoxy-16-hydroxy-prosten-1-ol-derivatives
US4291175A (en) * 1980-04-03 1981-09-22 American Cyanamid Company 1-Hydroxymethyl-11-deoxy-15-hydroxy-prosten-1-ol-derivatives
US4289910A (en) * 1980-04-03 1981-09-15 American Cyanamid Company 1-Hydroxymethyl-prosten-1-ol derivatives
US4301146A (en) * 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
US4399290A (en) * 1980-09-22 1983-08-16 E. I. Du Pont De Nemours And Company Optically active tert-alkyl 7-(2-oxo-5-carbonyloxypyrrolidinyl)heptanoates
US4459310A (en) * 1983-06-27 1984-07-10 G.D. Searle & Co. Method for cholesterol lowering
US4754059A (en) * 1984-11-07 1988-06-28 G. D. Searle & Co. Omega cycloalkyl prostaglandins
US4499296A (en) * 1983-11-14 1985-02-12 G. D. Searle & Co. Omega cycloalkyl prostaglandins
US4820728A (en) * 1985-11-25 1989-04-11 G. D. Searle & Co. Tetraenyl prostaglandins
US4847293A (en) * 1985-11-25 1989-07-11 G. D. Searle & Co. Tetraenyl prostaglandins
US4683328A (en) * 1985-11-25 1987-07-28 G. D. Searle & Co. Tetraenyl prostaglandins
US5011958A (en) * 1987-06-08 1991-04-30 G. D. Searle & Co. Process for preparing higher order cuprate complexes
US4785124A (en) * 1987-06-08 1988-11-15 G. D. Searle & Co. Process for preparing higher order cuprate complexes
US4777275A (en) * 1987-06-09 1988-10-11 G. D. Searle & Co. Process of preparing higher order cuprate complexes
US5055604A (en) * 1990-04-17 1991-10-08 G. D. Searle & Co. Process for preparing prostaglandin analogs using organozirconium compounds
US5252763A (en) * 1990-04-17 1993-10-12 G. D. Searle & Co. Process for preparing prostaglandin analogs
AU7793791A (en) * 1990-05-03 1991-11-27 G.D. Searle & Co. Pharmaceutical composition for use in treating pain
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
US5218139A (en) * 1990-12-27 1993-06-08 G. D. Searle & Co. Method for inhibiting IgE production
US5157052A (en) * 1990-12-27 1992-10-20 Monsanto Company Method for inhibiting ige production
US5324746A (en) * 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US5684177A (en) * 1996-05-17 1997-11-04 Torcan Chemical Ltd. Misoprostol
ATE236907T1 (de) * 1996-05-17 2003-04-15 Torcan Chemical Ltd Misoprostol, verfahren zur deren herstellung mit verwendung eines organometall-kupferkomplexes
WO1997045114A1 (en) * 1996-05-30 1997-12-04 Lysis Corporation The treatment of vascular disease with prostaglandins via a sustained-release dermal patch
US5994399A (en) * 1997-03-27 1999-11-30 Mckee; Rex N. Method of regenerating collagen-containing tissues with misoprostol
US6030959A (en) * 1997-04-04 2000-02-29 Monsanto Company Gastro-specific prodrugs
EP1005336A4 (en) 1997-07-09 2001-01-17 Androsolutions Inc IMPROVED METHODS AND COMPOSITIONS FOR TREATING MALE ERECTIONAL DISORDERS
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US5889051A (en) * 1997-07-15 1999-03-30 Development Center For Biotechnology Stabilization of prostaglandin drug
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
PT1563846E (pt) 2002-10-10 2012-11-13 Ono Pharmaceutical Co Promotores da produção de factores endógenos de reparação
EP1563845A4 (en) * 2002-10-10 2008-02-20 Univ Kyoto REMEDIES FOR ALLERGIC DISEASES
US20070270489A1 (en) 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
US7241746B2 (en) * 2003-08-06 2007-07-10 Regena Therapeutics, Lc Method and composition for treating periodontal disease
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20100010046A1 (en) * 2006-06-12 2010-01-14 Ironwood Pharmaceuticals, Inc. Pharmaceutical formulation for parenteral administration
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
WO2015056504A1 (ja) 2013-10-15 2015-04-23 小野薬品工業株式会社 薬剤溶出性ステントグラフト
HU231185B1 (hu) 2017-07-11 2021-07-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Eljárás Misoprostol előállítására és tisztítására
CN108753898A (zh) * 2018-04-09 2018-11-06 深圳市祥根生物科技有限公司 一种米索前列醇酸的制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812172A (en) * 1970-05-04 1974-05-21 Upjohn Co 15-methyl and 15-ethyl dihydro-pge1
ZA72646B (en) * 1971-03-11 1973-09-26 Upjohn Co Prostaglandin analogs
GB1444971A (en) * 1972-07-24 1976-08-04 American Cyanamid Co Derivatives of prostanoic acid

Also Published As

Publication number Publication date
DE2513212A1 (de) 1975-10-09
NL183294B (nl) 1988-04-18
NO146200B (no) 1982-05-10
DE2513212C2 (de) 1986-03-27
NL930058I1 (nl) 1993-09-01
EG12063A (en) 1978-09-30
FR2274289B1 (no) 1979-06-29
OA04910A (fr) 1980-10-31
IL46919A (en) 1979-12-30
BE827127A (fr) 1975-09-25
US3965143A (en) 1976-06-22
IL46919A0 (en) 1975-05-22
IE41328L (en) 1975-09-26
CH613443A5 (no) 1979-09-28
FI750899A (no) 1975-09-27
IE41328B1 (en) 1979-12-05
SE7503431L (no) 1975-09-27
GB1492426A (en) 1977-11-16
NL7503553A (nl) 1975-09-30
JPS50135059A (no) 1975-10-25
AU7947175A (en) 1976-09-30
CA1040197A (en) 1978-10-10
FR2274289A1 (fr) 1976-01-09
PH16276A (en) 1983-08-26
FI63747B (fi) 1983-04-29
ZA751391B (en) 1976-10-27
AR207355A1 (es) 1976-09-30
NO751039L (no) 1975-09-29
DK128075A (no) 1975-09-27
ATA227375A (de) 1979-01-15
ES436043A1 (es) 1977-01-16
PL100838B1 (pl) 1978-11-30
HU174973B (hu) 1980-04-28
JPS5855142B2 (ja) 1983-12-08
NL930058I2 (nl) 1994-02-16
YU73575A (en) 1982-02-28
YU39735B (en) 1985-04-30
SE420199B (sv) 1981-09-21
AT351684B (de) 1979-08-10
FI63747C (fi) 1983-08-10

Similar Documents

Publication Publication Date Title
NO146200C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme 16-oksygenerte prostansyrederivater
NO145691C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme decapeptidamider
NO157933C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme cefemforbindelser.
NO142401C (no) Analogifremgangsmaate til fremstilling av mavesyresekresjonshemmende 2-pyridylalkyltiobenzimidazoler
NO147450C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinazolonderivater
NO144418C (no) Fremgangsmaate til fremstilling av klorerte etenderivater
NO149281C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 7alfa-metoksycephalosporinderivater
SE7803860L (sv) Forfarande for framstellning av 7-d-(-)-alfa-amino-alfa(p-hydroxifenylacetamido)desacetoxicefalosporansyra
NO151040C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-halogenpyrimid-2-oner
NO143796C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme piperazinyliminorifamyciner
NO142303C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme oksazolderivater
SE409452B (sv) Forfarande for framstellning av stilbenderivat
NO146022C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme benzofenonderivater
NO141755C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme dotriacontapeptidamider
SE7506237L (sv) Forfarande for framstellning av dekahydroisokinolinderivat
NO144604C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme histidinderivater
SE7513739L (sv) Forfarande for framstellning av 2-scyl-4-oxo-pyrazino-isokonolin-derivat
SE414029B (sv) Forfarande for framstellning av terapeutiskt aktiva fentiazinderivat
NO139733C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive derivater av metylamin
SE7506196L (sv) Forfarande for framstellning av amidin-hydrazon-derivat
SE388854B (sv) Forfarande for framstellning av fenylpyridylaminderivat
NO144741C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiopyrano-pyrazoler
NO141608C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive alkanolaminderivater
NO145982C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme monokromon-forbindelser
SE418395B (sv) Forfarande for framstellning av indanettiksyror